3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboembolism
1
Pulmonary Embolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
Gemcitabine
54
130-nm albumin-bound paclitaxel
29
Magnetic Resonance Spectroscopy
21
Taxes
18
Fluorouracil
18
Specimen Handling
17
Oxaliplatin
17
Leucovorin
17
Drug Therapy
17
Albumin-Bound Paclitaxel
17
Irinotecan
14
pembrolizumab
13
Cyclophosphamide
11
Blood Specimen Collection
11
Biopsy
11
fludarabine
10
Radiosurgery
9
irinotecan sucrosofate
8
folfirinox
6
Magnetic Resonance Imaging
6
Cetuximab
6
Bevacizumab
6
dehydroftorafur
5
Surveys and Questionnaires
5
Nivolumab
5
Endoscopic Ultrasound-Guided Fine Needle Aspiration
5
sintilimab
4
olaparib
4
balstilimab
4
Surgical Procedures, Operative
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pancreatic Neoplasms
×
isoquercitrin
×
Clear all
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled